Long-Term Durability of Ciliary Neurotrophic Factor–Releasing Revakinagene Taroretcel-lwey in Individuals With Retinal Degenerative Disorders
This retrospective analysis suggests that a single, intraocular administration of revakinagene taroretcel-lwey provides sustained, bioactive CNTF for durations exceeding a decade, potentially providing a long-term treatment option for chronic retinal degenerative diseases.
Authors
- Lisa D. Orecchio
- Konrad Kauper
- Eugene Gonzalez‐Lopez (ORCID: https://orcid.org/0000-0002-4547-5144)
- Jay M. Stewart (ORCID: https://orcid.org/0000-0003-1054-3423)
- Alice Lee (ORCID: https://orcid.org/0000-0003-0188-0612)
- Jacque L. Duncan (ORCID: https://orcid.org/0000-0002-9593-6412)
- Thomas M. Aaberg
- Arne Nystuen
Institutions
- University of California, San Francisco (US)
- Neurotech (United States) (US)
- Retina Specialists of Michigan (US)
Publication Details
- Journal
- Investigative Ophthalmology & Visual Science
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1167/iovs.66.11.3
- Citations
- 3
- Primary Topic
- Retinal Development and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Research to Prevent Blindness
- Giannini Foundation of Agricultural Economics
- National Institutes of Health
- University of California, San Francisco
- National Eye Institute